DOI: http://dx.doi.org/10.18203/2349-2902.isj20220338

A prospective study on the correlation between clinical outcome and residual prostatic adenoma weight ratio after transurethral resection of the prostate for benign prostatic hyperplasia

Y. P. S. Rana, Yogesh K. Swami

Abstract


Background: Transurethral resection of the prostate (TURP) has been the most common surgical method for relieving symptoms of benign prostatic hyperplasia (BPH). However, there is no consent regarding the amount of tissue resected during TURP and it’s persuading on ruling of symptoms. Therefore the aim of the present study was to assess the correlation between clinical outcome and residual prostatic adenoma weight ratio after transurethral resection of the prostate for benign prostatic hyperplasia.

Methods: A total of 70 patients presenting with obstructive/irritative lower urinary tract symptoms were evaluated for pre and post TURP values of prostatic weight, international prostate symptoms score (IPSS), postvoid residual volume (PVR), maximum flow rate (Q-max) and total prostate volume (TPV). Residual prostatic weight ratio (RPWR) was recorded in each case using transrectal ultrasound.

Results: The effectiveness of TURP was 71.42%. On appraisal of the patients for IPSS, PVR, Q-max and TPV; the difference between pre-operative and post-operative values of these parameters was found to be statistically significant p<0.001. RPWR was found to be significantly lower (p<0.001) in patients who received valuable treatment. A strong linear correlation was found between total prostate and transition zone volumes in all groups.

Conclusions: Values of IPSS, PVR, Q-max, TPV and operative parameters such as RPWR and residual prostatic weight are important parameters for the prediction of treatment outcome.


Keywords


Clinical outcome, Residual prostatic weight, Transurethral resection of prostate, Prostatic hyperplasia

Full Text:

PDF

References


Lee C, Kozlowski J, Grayhack J: Intrinsic and extrinsic factors controlling benign prostatic growth. Prostate. 1997;31:131.

Auffenberg G, Helfan B, McVary K: Established medical therapy for benign prostatic hyperplasia. Urol Clin North Am. 2009;36:443.

Reynard J. Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? Curr Opin Urol. 2004;14:13.

Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hypertrophy with age. J Urol. 1984;132:474-9.

Barry MJ, Fowler FJ, O'Leary M, Bruskewitz RJ, Holtgrewe HL, Mebust WK, Cocket AT. The American Urological Association symptom index for benign prostatic hyperplasia. The measurement committee of the American Urological Association. J Urol. 1992;148:1549-55.

Speakman MJ. Who should be treated and how? Evidence based medicine in symptomatic BPH. Eur Urol. 1999;36(3):21-7.

Hastak SM, Gammelgard J. Holm HH. Tran rectal ultrasonic volume determination of the prostate- a preoperative and postoperative study. J Urol. 1982;127:1115-8.

Green JS, Bose P, Thomas DP, Thomas K, Clements R, Peeling WB, Bowsher WG. How complete is a transurethral resection of the prostate? Br J Urol. 1996;77(3):398-400.

McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793-803.

McConnell J, Roehrborn C, Bautista O. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387.

Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med. 1995;332:75.

Vela-Navarrete R, Gonzalez-Enguita C, Garcia-Cardoso JV, Manzarbeitia F, Sarasa-Corral JL, Granizo JJ:The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002). BJU Int. 2005;96:1045-8.

Reich O, Gratzke C, Stief CG. Techniques and long-term results of surgical procedures for BPH. Eur Urol. 2006;49:970.

Abrams P, Chapple C, Khoury S, Roehrborn C, de la Rosette J; International Scientific Committee. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol. 2009;181(4):1779-87.

Nesbit RM. Transurethral prostatic resection. In: Campbell L, Harrison J, editors. Urology. Philadelphia, Sounders. 1970;2479.

Antunes AA, Srougi M, Coelho RF, Leite KR, Freire Gde C. Transurethral resection of the prostate for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: how much should be resected? Int Braz J Urol. 2009;35(6):683-9.

Hakenberg OW, Helke C, Manseck A, Wirth MP. Is there a relationship between the amount of tissue removed at transurethral resection of the prostate and clinical improvement in benign prostatic hyperplasia. Eur Urol. 2001;39:412-7.

Nagarathnam M, Latheef SAA. Prevalence of lower urinary tract symptoms inpatients of benign prostatic hyperplasia attending Tertiary Care Hospital in the State of Andhra Pradesh. J Dr. NTR University of Health Sciences. 2017;6:154-7.

Aagaard J, Jonler M, Fuglsig S, Christensen LL, Jorgensen HS, Norgaard JP. Total transurethral resection versus minimal transurethral resection of the prostate--a 10-year follow-up study of urinary symptoms, uroflowmetry and residual volume. Br J Urol. 1994;74:333-6.

Agrawal MS, Aron M, Goel R. Hemiresection of the prostate: short-term randomized comparison with standard transurethral resection. J Endourol. 2005;19:868-72.

Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications.A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol. 1989;141:243.

Hahn R, Fagerstrom T, Tammela T. Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride. BJU Int. 2007;99:587.

Goh M, Mohan D. Bipolar Vs Monopolar resection of the prostate (TURP) For benign prostatic obstruction: A randomised prospective trial comparing treatment efficacy and the incidence of Transurethral resection syndrome. J Urol. 2010;184(4):739.

Watanabe H, Igari D, tanahashi YY, Harada K, Sasitoh M. Measurement of size and weight of prostate by means of Tran rectal ultrasonography. Tokohu J Exp Med. 1974;114:277.

Miyazaki Y, Yamaguchi A, Hara S, The value of transrectal ultrasonography in preoperative assessment for transurethral prostatectomy. J Urol. 1983;129;48-50.

Matthews GJ, Motta J, Fracehia JA. The accuracy of transrectal ultrasound prostate volume estimation: clinical correlations. J Clin Ultrasound. 1996;24:501-5.

Mc Neal JE. The zonal anatomy of the prostate. The Prostate. 2006;2(1)35-49.

Zlotta AR, Djavan B, Damoun M, Roumeguere T, Petein M, et al. The importance of measuring the prostatic transition zone: an anatomical and radiological study. Br J Urol. 1999;84:661-6.

Desai MM. Transrectal ultrasound parameters: presumed circle area ratio and transitional zone area in the evaluation of patients with lower urinary tract symptoms. J Endourol. 1999;13:317.

Greene DR, Egawa S, Hellerstein DK, Scardino PT. Sonographic measurements of transition zone of prostate in men with and without benign prostatic hyperplasia. Urology. 1990;36:293-9.

Marks LS, Partin AW, GormleyGJ, Dorey FJ, et al. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. J Urol. 1997;157:2171-8.

Tewari A, Indudhara R, Shinohara K. Comparison of transrectal ultrasound prostatic, estimation with magnetic resonance imaging, estimation and surgical specimen weight in patients with benign prostatic hyperplasia. J Clin Ultrasound. 1996;24:169-74.

Terris MK, Afzal N, Kabalin JN. Correlation of transrectal ultrasound measurements of prostate and transition zone size with symptom score, bother score, urinary flow rate, and post-void residual volume. Urology. 1998;52(3):462-6.

Kaplan SA, Te AE, Pressler LB, Olsson CA. Transition zone index as a method of assessing benign prostatic hyperplasia: Correlation with symptoms, urine flow and detrussor pressure. J Urol. 1995;154:1764-9.

Hakenberg OW, Helke C, Manseck A, Wirth MP. Is there a relationship between the amount of tissue removed at transurethral resection of the prostate and clinical improvement in benign prostatic hyperplasia. Eur Urol. 2001;39(4):412-7.

Lepor H, Nieder A, Feser J, O’Connell C. Total prostate and transitional zone volumes and transition zone index are poorly correlated with objective measures of clinical benign prostatic hyperplasia. J Urol. 1997;158:85-8.

Chen SS, Hong JG, Hsiao YJ, Chang LS. The correlation between clinical outcome and residual prostatic weight ratio after transurethral resection of the prostate for benign prostatic hyperplasia. BJU Int. 2000;85:79-82.

Derrett S, Paul C, Herbison P. Prospective evaluation of the effects of prostatectomy on symptoms and quality of life. NZ Med J. 2001;114(1134):276-9.

Uchida T, Ohori M, Soh S, Sato T, Iwamura M, Ao T, et al. Factors influencing morbidity in patients undergoing transurethral resection of the prostate. Urology. 1999;53:98-105.

Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention. Eur Urol. 2006;50:969-79.